H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback
AI Summary
H.C. Wainwright has reaffirmed its stock rating for Entera Bio following feedback from the FDA. The update reflects ongoing investor interest and confidence in the company's developments tied to regulatory progress.